Vitreous levels of interleukin-35 as a prognostic factor in B-cell vitreoretinal lymphoma

Atsunobu Takeda1,6,* , Eiichi Hasegawa1, Shintaro Nakao7, Keijiro Ishikawa1, Yusuke Murakami2, Toshio Hisatomi2, Mitsuru Arima1, Nobuyo Yawata1,5, Yoshinao Oda3, Kazuhiro Kimura4, Hiroshi Yoshikawa1 & Koh-Hei Sonoda1,5

Vitreoretinal lymphoma (VRL) is a rare disease of B-cell origin with poor prognosis. Regulatory cytokines promote tumor development by suppressing antitumor immunity in several cancer types, including B-cell malignancies. To identify the regulatory cytokines associated with poor prognosis in patients with B-cell VRL, we determined the regulatory cytokines profiles in the vitreous humor of patients with VRL. This retrospective study included 22 patients with VRL, 24 with non-infectious uveitis (NIU), and 20 with idiopathic epiretinal membrane (control). Vitreous concentrations of regulatory cytokines were assessed using a cytometric beads assay and association with clinical data was examined. IL-35 and soluble IL-2 receptor α levels were significantly higher in patients with VRL and NIU than those in the control group. The 5-year overall survival (OS) rates for the group with high intravitreal IL-35 was significantly poorer than those for the group with low intravitreal IL-35, who were diagnosed with VRL at the onset (P = 0.024, log-rank test). The 5-year OS rates with intravitreal IL-35 levels above and below the median were 40.0% and 83.3%, respectively. Our results suggest that high intravitreal IL-35 levels indicate poor prognosis for patients diagnosed with B-cell VRL at the onset.

The majority of vitreoretinal lymphomas (VRLs) are related to a high-grade non-Hodgkin’s lymphoma (NHL) which is a subset of primary central nervous system lymphoma (PCNSL) that can be subtyped as diffuse large B-cell lymphoma (DLBCL).1 VRL often occurs in elderly immunocompetent patients and usually develops in the retina, vitreous chamber, and/or the optic nerve2. Most VRLs either present as primary lymphomas, or they occur secondarily to or simultaneously with central nervous system (CNS) lymphomas. In rare cases, VRLs are derived from systemic metastatic lymphomas1,3. Primary VRL (PVRL) is a rare form of VRL that is limited to the eye at initial diagnosis; at a referral eye center in Japan, its incidence rate is estimated to be 21 per 100,000 patients with ocular disorders4. CNS involvement (an indicator of poor prognosis) develops after the onset of ocular symptoms in 60–90% of PVRL patients5,6. Recently, several prospective studies have demonstrated that HD-MTX-based chemotherapy with intravitreal MTX injections could delay the progression of VRL to the CNS, thus improving overall survival (OS)7–9. However, it is often difficult to administer these treatments to elderly patients and patients with a poor general condition due to the possibility of treatment-induced adverse events, such as neurotoxicity and nephrotoxicity10,11.

The tumor microenvironment (TME) composed of reactive immune cells, stromal cells, blood vessels, and extracellular matrix, regulates tumor cell survival and proliferation, as well as immune evasion for treatment resistance, and is associated with worse prognosis in B-cell malignancies12. In PCNSL specimens, tumor-infiltrating lymphocytes (TILs) are found in the perivascular area, accompanied by the accumulation of lymphoma cells around the vessels within the tumor13. Recently, several studies have reported that regulatory cytokines in the...
TME, such as interleukin (IL)-10 and IL-35, support tumor development via the suppression of antitumor immunity in cancer\textsuperscript{14–16}. Regulatory T-cells (Tregs), which belong to a highly suppressive subset of T-cells, increase regulatory cytokine secretion for the maintenance of self-tolerance and inhibition of autoimmunity, resulting in tumor development\textsuperscript{17–18}. IL-10 is widely regarded and has been analyzed as an immunosuppressive cytokine; it not only exerts inhibitory effects on antitumor immunity by Tregs but is also a potent growth and survival factor for malignant B cells, leading to the exacerbation of B-cell lymphoma\textsuperscript{14}. IL-35 is a heterodimeric cytokine, comprising IL-12p35 and Epstein-Barr-induced gene 3 (EBI3) subunits, and is categorized as a IL-12-related cytokine. IL-35 is reported to possess anti-inflammatory and immunosuppressive roles due to its inhibitory effect on the effector T-cell function by the induction of IL-10, and expansion of Tregs and regulatory B cells\textsuperscript{19}. IL-35 was also shown to inhibit potent antitumor immunity through the increased expression of inhibitory receptors, such as programmed cell death-1 (PD-1) and T-cell immunoglobulin and mucin domain 3, on TILs in the TME\textsuperscript{16}. Furthermore, IL-10-related cytokines, such as IL-22, have been identified in sequence homology search for IL-10\textsuperscript{20} and reported to have a regulatory role in ocular inflammatory diseases such as uveitis\textsuperscript{21–23}. Thus, the assessment of regulatory cytokines may bring about better comprehension of B-cell VRL pathogenesis, leading to their clinical use, such as in diagnostic markers and therapeutic targets.

In this study, we aimed to reveal the profiles of regulatory cytokines in the vitreous humor of VRL patients, and compare these with those of non-infectious uveitis (NIU) patients. In addition, we assessed the association of regulatory cytokines with clinical parameters in B-cell VRL patients; and observed that higher levels of IL-35 in the vitreous humor were positively correlated with a poor prognosis in B-cell VRL patients with vitreoretinal lesions at initial diagnosis.

Results
The following VRL patients’ (n = 22) clinical data are presented in Table 1: (1) age at diagnosis of VRL, (2) sex, (3) the eye involved, (4) primary organ involved, (5) presence or absence of HD-MTX-based chemotherapy for CNS prophylaxis or CNS lesions after the initial onset of VRL, (6) presence or absence of HD-MTX-based chemotherapy for the treatment for PCNSL before the initial onset of VRL, (7) brain involvement, (8) relapses after initial diagnosis of malignant lymphoma, and (9) interval between the initial definitive diagnosis of B-cell VRL and death.

Vitreous levels of regulatory cytokines. The data for the vitreous levels of regulatory cytokines obtained from patients with controls, VRL, and NIU are summarized in Table 2. IL-10, IL-20, IL-22, IL-27, IL-35, and soluble IL-2 receptor α (sIL-2Rα) levels were significantly different among patients with controls, VRL, and NIU (Table 2; P < 0.001, P < 0.001, P = 0.011, P = 0.026, P < 0.001, P < 0.001, respectively). Vitreous levels of IL-22 (P = 0.0044) and IL-10 (P < 0.001) were significantly higher in patients with VRL than those with NIU and controls, whereas none was higher in patients with NIU than those with VRL and the control groups. IL-20 levels (P = 0.015) were decreased in patients with NIU compared to those with VRL and the control groups. Vitreous levels of IL-35 (P < 0.001) and sIL-2Rα (P < 0.001) were increased in patients with VRL and NIU compared to controls, but were comparable in between patients with VRL and NIU. IL-27 levels (P = 0.027) were elevated in patients with VRL compared to controls but were comparable to those with NIU. IL-12p40 and IL-26 levels were not significantly different among the three groups. IL-2, IL-12p70, IL-19, IL-28A/IFN-λ2, and IL-29/IFN-λ1 levels in each group were under the detection limit (data not shown).

Elevation of vitreous IL-35 levels may be a prognostic factor in patients with VRL. For the 17 patients with B-cell VRL who were followed for more than 5 years, the 5-years OS rate was 58.8% (10/17, Fig. 1). We assessed the association of OS with vitreous levels of regulatory cytokines and sIL-2Rα, the density of CD3\textsuperscript{+} cells in the vitreous humor, age, and sex in patients with VRL. First, to divide 22 patients with VRL into 17 patients with B-cell VRL who were followed for more than 5 years, the 5-years OS rate was 58.8% (10/17, one patient in each group was treated with IV-MTX alone due to their old age and general condition. The strong correlation of IL-35 and sIL-2Rα levels with the density of CD3\textsuperscript{+} cells in the vitreous body in patients with VRL. We previously reported that there is a statistically significant positive correlation between the density of CD3\textsuperscript{+} cells in vitrectomy cell blocks and the vitreous levels of sIL-2Rα in patients with VRL\textsuperscript{27}. Therefore, we examined whether the vitreous levels of IL-35 and sIL-2Rα were related to the density of CD3\textsuperscript{+} cells in vitrectomy cell blocks in patients with VRL (n = 16). There was a statistically significant positive correlation between the-
Table 1. Clinical data of patients with VRL. VRL, vitreoretinal lymphoma; F, female; M, male; OU, both eyes; OS, left eye; mos., months; ca., carcinoma; LN, lymph node; N/A, not applicable; ML, malignant lymphoma.

| Case no. | Sex | Age at diagnosis of B cell lymphoma (year) | Primary origin | Eye involved | HD-MTX-based chemotherapy after vitreoretinal relapse | Brain involved | HD-MTX-based chemotherapy before vitreoretinal relapse | Brain involved | Relapse (mos. after initial diagnosis) | Outcome (mos. after initial diagnosis of vitreoretinal lesions) |
|----------|-----|------------------------------------------|----------------|--------------|------------------------------------------------------|---------------|--------------------------------------------------------|---------------|-------------------------------------|------------------------------------------------------------------|
| 1        | F   | 51                                       | Eye OU         | Yes          | N/A                                                  | Yes           | Brain                                                 | Yes           | 16 mos Eye; no relapse | Died 38 mos                                                      |
| 2        | F   | 55                                       | Eye OU         | Yes          | N/A                                                  | Yes           | Brain                                                 | Yes           | 80 mos Eye; 20 mos | Alive                                                            |
| 3        | F   | 80                                       | Eye OS         | No           | N/A                                                  | Yes           | Brain                                                 | No            | 12 mos Eye; no relapse | Died 18 mos                                                      |
| 4        | M   | 45                                       | Eye OU         | Yes          | N/A                                                  | Yes           | Brain                                                 | Yes           | 48 mos Eye; 26 mos | Died 83 mos                                                      |
| 5        | F   | 73                                       | Eye and Brain OU | No          | N/A                                                  | Yes           | Brain                                                 | Yes           | 16 mos Eye; no relapse | Died 25 mos                                                      |
| 6        | F   | 67                                       | Eye and Brain OU | Yes         | N/A                                                  | Yes           | Brain                                                 | No            | no relapse; Alive     |                                                                  |
| 7        | F   | 68                                       | Eye OU         | Yes          | N/A                                                  | Yes           | Brain                                                 | Yes           | 68 mos; 52 mos | Died 71 mos                                                      |
| 8        | M   | 68                                       | Eye OU         | Yes          | N/A                                                  | Yes           | Brain                                                 | Yes           | 53 mos Eye; 32 mos | Died 70 mos                                                      |
| 9        | M   | 68                                       | Eye and Brain OU | Yes         | N/A                                                  | Yes           | Brain                                                 | Yes           | 20 mos Eye; 20 mos | Died 43 mos                                                      |
| 10       | F   | 65                                       | Eye OU         | Yes          | N/A                                                  | Yes           | Brain                                                 | Yes           | 64 mos Eye; 24 mos | Alive                                                            |
| 11       | F   | 70                                       | Eye and Brain OU | Yes         | N/A                                                  | Yes           | No relapse                                            | Yes           | Alive                                                            |
| 12       | M   | 63                                       | Brain OU       | Yes          | Yes                                                  | Yes           | Eye                                                  | Yes           | 10 mos | Died 48 mos                                                      |
| 13       | M   | 61                                       | Brain OU       | Yes          | Yes                                                  | Yes           | Eye                                                  | Yes           | 20 mos Lost to follow-up |                                                                 |
| 14       | M   | 59                                       | Brain OU       | Yes          | Yes                                                  | Yes           | Eye                                                  | Yes           | 33 mos Lost to follow-up |                                                                 |
| 15       | M   | 38                                       | Brain OS       | Yes          | Yes                                                  | Yes           | Eye                                                  | Yes           | 6 mos Lost to follow-up |                                                                 |
| 16       | F   | 69                                       | Brain OU       | No           | Yes                                                  | Yes           | Eye                                                  | Yes           | 35 mos Alive |                                                                  |
| 17       | M   | 66                                       | Brain OU       | Yes          | Yes                                                  | Yes           | Eye                                                  | Yes           | 84 mos | Died 44 mos                                                      |
| 18       | F   | 73                                       | Nose, Paranasal sinus OU | No         | Yes                                                  | Yes           | Eye                                                  | Yes           | 120 mos Brain; 102 mos | Alive                                                            |
| 19       | M   | 78                                       | Chest wall OU  | Yes          | No                                                   | Yes           | Eye                                                  | Yes           | 18 mos Brain; 24 mos | Alive                                                            |
| 20       | F   | 74                                       | Breast OU      | No           | No                                                   | No            | Eye                                                  | Yes           | 59 mos Brain; no relapse | Died 30 mos, but not due to ML                                   |
| 21       | M   | 68                                       | Testis OS      | Yes          | No                                                   | Yes           | Eye                                                  | Yes           | 108 mos Brain; 96 mos | Died 24 mos                                                      |
| 22       | F   | 79                                       | Intestine OU   | No           | No                                                   | No            | Eye                                                  | Yes           | 19 mos Lost to follow-up |                                                                 |

Table 2. Concentrations of regulatory cytokines and sIL-2Ra in the vitreous humor. VRL, vitreoretinal lymphoma; IL, interleukin; s, soluble; R, receptor. Cytokines and sIL-2Ra are expressed as median with interquartile range in parentheses. *Kruskal–Wallis test. †One-way ANOVA test. 5P < 0.05: VRL or uveitis vs control. 55P < 0.01: VRL or uveitis vs control. 55P < 0.05: VRL or control vs uveitis. 555P < 0.01: VRL or control vs uveitis: Steel–Dwass test or Turkey–Kramer test.
sity of CD3+ cells and the vitreous levels of IL-35 as well as those of sIL-2Rα in patients with VRL ($r = 0.7148$, $P = 0.0013$; $r = 0.5519$, $P = 0.022$; Spearman correlation coefficient: Fig. 4A,B).

**Discussion**
In this study, we identified differential profiles of regulatory cytokines between patients with B-cell VRL and NIU. The profiles of regulatory cytokines in the vitreous humor showed higher levels of IL-10 and IL-22 in patients with VRL than those in patients with NIU and the controls; and higher levels of IL-35 and sIL-2Rα in patients with VRL and NIU than those with the controls, and higher levels of IL-27 in patients with VRL than those with the controls. In our analysis of regulatory cytokines with clinical parameters, higher levels of IL-35 were
indicative of a poor outcome in the vitreous humor at the initial diagnosis of B-cell VRL. In addition, levels of IL-35 and sIL-2Rα were positively correlated with the density of CD3+ cells in the vitreous humor in B-cell VRL.

Although responses to HD-MTX-based systemic chemotherapy and/or WBRT for CNS prophylaxis or CNS lesions were effective or led to complete remission (CR) in patients with VRL in this study, the effects of the treatment were limited and not long-lasting. Recently, nivolumab, an anti-PD-1 agent, has been reported to maintain CR in patients with relapsed/refractory PCNSL. PD-1, which is expressed on activated T-cells, such as cytotoxic T lymphocytes (CTLs), interacts with its ligands PD-L1 and PD-L2, which are commonly expressed by tumor cells, leading to enhanced inhibitory signaling of T-cell receptor in CTLs. IL-35 can directly upregulate the expression of PD-1 receptors on Tregs and myeloid-derived suppressor cells (MDSCs) to weaken the T-cell mediated antitumor immunity by promoting their inhibitory function and T-cell exhaustion in TIL. This suggests that immune check-point inhibitors, targeting PD-1 or PD-L1, are effective for CNS prophylaxis in patients with PVRL or in patients with recurrent or refractory DLBCL-VRL when IL-35 levels are high in the vitreous humor at the initial diagnosis. In addition, blocking IL-35 is one of the appealing targets to improve prognosis in patients with recurrent or refractory DLBCL-VRL, for whom the concentration of IL-35 is regarded as high in the vitreous humor.

IL-35 is secreted not only by Treg, but also by B cells, monocytes, endothelial cells, and smooth muscle cells at a lesser amount. IL-35 can activate Tregs and convert naive T-cells into IL-35-producing induced Treg subsets (iTr35 cells), which accumulate in the TME and exert robust suppressive activity. Sawant et al. demonstrated that Treg-derived IL-10 and IL-35 in the TME cooperatively limited antitumor immune responses by regulating the expression of several inhibitory receptors and T-cell exhaustion in CD8+ TIL. The histological analysis of breast cancer samples revealed that high IL-35 levels in TILs were significantly associated with advanced cancer stages, resulting in poor PFS and OS. Furthermore, in colorectal cancer patients, IL-35 expression was correlated with the severity of malignancy, cancer clinical stage, and the number of peripheral Foxp3+Tregs. Moreover, IL-35 expression was defined as an independent prognostic factor for recurrence and positively correlated with CD39+Foxp3+TILs infiltration in hepatocellular carcinoma. Therefore, these reports together with our own results suggest that Tregs in TIL are the primary source of IL-35 and that IL-35 is involved in the formation of the TME and subsequent tumor progression in patients with B-cell VRL. Furthermore, it is reported that tumor-derived IL-35 promotes MDSCs accumulation in the TME, tumor angiogenesis, and suppression of CTL responses to support tumor growth. In addition, gene expression analysis in DLBCL samples has revealed that increased expression of IL-35 in tumor cells is associated with a worse OS in patients with DLBCL that are treated with systemic chemotherapy. Therefore, our results indicated that higher levels of IL-35 could be induced from DLBCL-VRL cells as well as Tregs in the high-IL-35 group than the low-IL-35 group, resulting in the inhibition of antitumor responses. Furthermore, IL-10 and IL-35 augmented their cooperation to limit antitumor immunity by inducing inhibitory receptors, including PD-1, and contributing to T-cell exhaustion of CD8+ Tregs once the tumor cells recurred, because IL-10 was abundantly secreted by tumor cells in B-cell VRL.

IL-27 was also reported to play an inhibitory role in antitumor immunity in several types of cancers. IL-27 is a heterodimeric cytokine and one of its subunits, EB13, is shared with IL-35. IL-27 possesses a proinflammatory or protective role in autoimmune diseases. However, IL-27 was shown to promote CTL and natural killer cell recruitment into the TME, thereby augmenting antitumor immunity. Immunohistological analysis of DLBCL demonstrated that no expression of IL-27p28, another subunit of IL-27, despite the overexpression of both EB13 and IL-35p35, which are components of IL-35. In our study, IL-27 levels were upregulated but not associated with the prognosis of patients with B-cell VRL, indicating that IL-27 may not be related to the inhibition of the antitumor immunity in B-cell VRL.

Previously, we have shown that sIL-2Rα levels anticipate tissue destruction events caused by the infiltration of T-cells into the neural retina and/or subretina in VRL. In this study, we found that sIL-2Rα levels were not associated with poor OS and PFS in patients with VRL. However, several studies have reported that serum sIL-2Rα levels predict well unfavorable prognosis in systemic DLBCL. The complex of sIL-2Rα and IL-2 promotes IL-2-dependent Tregs development and function, and inhibits CD8+ T-cells, supporting B-cell lymphoma growth. Recently, Yoshida et al. revealed that sIL-2Rα levels in sera are dependent on the infiltration of tumor-associated macrophages (TAM) into the TME. TAM-derived matrix metalloproteinase-9 plays a pivotal role in the cleavage of IL-2Rα on T-cells in extranodal DLBCL and follicular lymphoma. TAM accumulate within the
TME, promoting tumor development, invasion, and metastasis. Overall, our data, aligned with these studies, suggest that sIL-2Ra levels are associated with the infiltration of TAM and CD3+ T-cells into the neural retina and/or subretina for promoting tumor invasion, rather than Tregs, which suppress antitumor immunity in VRL.

Th22 cells were shown to be associated with the development and progression of various types of cancers, including B-cell NHL. Th22 cells, which are newly defined subsets of T helper cells, are a source of IL-22 and TNF-α. Recently, IL-22 was found to promote tumor growth in multiple myeloma and mantle cell lymphoma through the aberrant expression of the IL-22 receptor. In addition, although increased frequency of Th22 cells was associated with plasma IL-22 levels because IL-22 is produced not only by Th22 cells but also various other types of cells, such as activated T-cells and NK cells. Our assessment of IL-10-related cytokines revealed that the levels of IL-22 were higher in patients with VRL than those of the patients with NIU and the controls, but were not associated with the prognosis of patients with VRL. Thus, these results suggested that increased levels of IL-22 are related to the development of B-cell VRL and that the source of IL-22 is not limited to Th22 cells, resulting in no association between IL-22 levels and worse outcome in our study. Further studies are necessary to study a role of Th22 cells in the pathogenesis of B-cell VRL.

There are some limitations to this study. First, because it is a single-center retrospective study, the registration information, patient volume, and variables assessed could not be designed beforehand. A bias of selection may have happened. Second, due to the shortage of samples, the sample size is small. Multicenter studies with a larger sample size may be required to clarify whether IL-35 levels are associated with the prognosis of VRL.

Performing the multiplex bead analyses of vitreous samples in patients with VRL, we determined that IL-35 might suppress antitumor immunity to promote tumor growth in VRL, contributing to poor prognosis of patients with VRL. The potential targeting of immune mediators such as immune check point inhibitors and neutralizing IL-35 warrants further research to develop new diagnostic and treatment strategies.

Materials and methods

Patients. This study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Kyushu University Institutional Review Board for Clinical Research. We obtained written informed consent from all the participants before performing any study procedures or examinations.

We examined the eyes of 22 immunocompetent patients with VRL (all classified as DLBCL; 10 men and 12 women; mean age, 65.4 ± 10.6 years), including 11 patients with PVRL and VRL with concurrent CNS lesions (VRCNSL), and 11 patients with secondary VRL (6 patients from PCNSL, one patient from testis, and four patients from systemic lesions except for CNS and testis). We also examined 24 patients with NIU (7 men and 17 women; mean age, 62.0 ± 9.88 years) and 20 patients with idiopathic epiretinal membrane (ERM) (7 men and 13 women; mean age, 66.3 ± 7.55 years) as negative controls at the Department of Ophthalmology, Kyushu University Hospital, between January 2008 and December 2019. All patients were Asian adults. VRL confined to the eyes at initial diagnosis was defined as PVRL. VRL accompanied by CNS lesions at initial diagnosis was defined as VRCNSL. Secondary VRL was defined as SVRL. The diagnosis of patients with VRL was based on the definitive identification of malignant lymphoid cells in the eye using either cytological smear or vitrectomy cell block technique.

The patients with preoperative trauma, pre-existing macular pathologies, vitreous hemorrhage, and diabetes mellitus, which are likely to affect the immune mediators in the vitreous humor, were excluded from the study.

Measurement of regulatory cytokines and the density of CD3+ cells. After diluting the above-mentioned supernatants collected from the vitreous body with 10× phosphate buffered saline, the concentration of each of the following regulatory cytokines was measured using Luminex 100 (Luminex, Austin, TX, USA) according to the manufacturer’s directions: Human regulatory cytokines; IL-2, IL-10, IL-12 (p40), IL-12 (p70), IL-19, IL-20, IL-22, IL-26, IL-27 (p28), IL-28A/IFN-λ2, IL-29/IFN-λ1, and IL-35 using Biorad Human T-regplex (Temse, Belgium) and sIL-2Ra using Milliplex MAP Human Soluble Cytokine Receptor Panel (St. Charles, MO, USA). Levels of regulatory cytokines and sIL-2Ra were obtained from the standard curves for each. When the concentrations were below the detection limit, they were coded as zero and were included in the statistical analysis.

When investigating the correlation of regulatory cytokines with the density of CD3+ cells, we used the data we had reported previously for the density of CD3+ cells.

Statistical analysis. The data were analyzed using Jump software version 14 (Business Unit of SAS, Cary, NC). If the data were normally and equally distributed, a one-way analysis of variance (ANOVA) was used to compare the vitreous concentrations of each cytokine among the groups, followed by Turkey–Kramer test to detect significant differences between VRL, NIU, and controls. If the data were not distributed normally or equally, the Kruskal–Wallis test was performed to compare the vitreous levels of each regulatory cytokine and sIL-2Ra, followed by Steel–Dwass test to detect significant differences between the three groups. Two-group comparisons of numerical variables were performed using the Mann–Whitney’s U test. OS was measured from the time of definitive diagnosis of VRL to death by any cause. PFS was measured from the time of definitive diagnosis of VRL to relapse or death by DLBCL. Patients with VRL were divided into two groups based on the median vitreous levels of each regulatory cytokine and sIL-2Ra. The Kaplan–Meier method was used to estimate the survival curves for each vitreous levels of regulatory cytokines and sIL-2Ra, the density of CD3+ cells in the vitreous humor, age, and sex, and the differences between the curves were evaluated by the log-rank test. To determine a correlation between T-cell density and levels of IL-35 or sIL-2Ra, Spearman correlation tests were used. P value < 0.05 was considered to be significant.
Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 13 March 2020; Accepted: 7 September 2020
Published online: 24 September 2020

References
1. Coupland, S. E., Chan, C. C. & Smith, J. Pathophysiology of retinal lymphoma. Ocul. Immunol. Inflamm. 17, 227–237. https://doi.org/10.1080/09273909093166066 (2009).
2. Faiya, J., Chan, C. C. Diagnosis of systemic metastatic retinal lymphoma. Arch. Pathol. Lab. Med. 133, 1228–1232. https://doi.org/10.1043/1543-2165-133.8.1228 (2009).
3. Cao, X., Shen, D., Callanan, D. G., Mochizuki, M. & Chan, C. C. Diagnosis of systemic metastatic retinal lymphoma. Acta Ophthalmol. 89, e149–154. https://doi.org/10.1111/j.1755-3768.2009.01797.x (2011).
4. Mochizuki, M. & Singh, A. D. Epidemiology and clinical features of intraocular lymphoma. Ocul. Immunol. Inflamm. 17, 69–72. https://doi.org/10.1080/09273909.2009.975305 (2009).
5. Chan, C. C. & Sen, H. N. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov. Med. 15, 93–100 (2013).
6. Kimura, K., Usui, Y. & Goto, H. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn. J. Ophthalmol. 56, 383–389. https://doi.org/10.1007/s00277-012-0150-7 (2012).
7. Kreher, S. et al. Prognostic impact of intraocular involvement in primary CNS lymphoma: Experience from the G-PCNSL-SGI trial. Ann. Hematol. 94, 409–414. https://doi.org/10.1007/s00277-014-2212-z (2015).
8. Akiyama, H. et al. High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma. Cancer Sci. 107, 1458–1464. https://doi.org/10.1111/cas.13012 (2016).
9. Kaburaki, T. et al. Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma. Br. J. Haematol. 179, 246–255. https://doi.org/10.1111/bjh.14848 (2017).
10. Correa, D. D. et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol. 14, 101–108. https://doi.org/10.1093/neuonc/nor186 (2012).
11. Kasenda, B. et al. The role of whole brain radiation in primary CNS lymphoma. Blood 128, 32–36. https://doi.org/10.1182/blood-2016-01-651016 (2016).
12. Fowler, N. H. et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 101, 531–540. https://doi.org/10.3324/haematol.2015.139493 (2016).
13. Venetz, D. et al. Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. Int. J. Cancer 127, 2300–2312. https://doi.org/10.1002/ijc.25236 (2010).
14. Czarnecki, J. et al. Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma. Leukemia 18, 597–606. https://doi.org/10.1038/sj.leu.2403244 (2004).
15. Douglas, R. S., Capocasale, R. J., Lamb, R. J., Nowell, P. C. & Moore, J. S. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood 89, 941–947 (1997).
16. Turnis, M. E. et al. Interleukin-21 limits anti-tumor immunity. Immunity 41, 316–329. https://doi.org/10.1016/j.immuni.2016.01.013 (2016).
17. Vignali, D. A., Collison, L. W. & Workman, C. J. How regulatory T cells work. Nat. Rev. Immunol. 8, 523–532. https://doi.org/10.1038/nri2343 (2008).
18. Nishikawa, H. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol. 27, 1–7. https://doi.org/10.1016/j.coi.2013.12.005 (2014).
19. Wang, Z. et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J. Immunol. 190, 2415–2423. https://doi.org/10.4049/jimmunol.1202535 (2013).
20. Burmeister, A. R. & Marriott, I. The interleukin-10 family of cytokines and their role in the CNS. Front Cell Neurosci. 12, 458. https://doi.org/10.3389/fncel.2018.00458 (2018).
21. Sun, D., Liang, D., Kaplan, H. J. & Shao, H. The role of Th17-associated cytokines in the pathogenesis of experimental autoimmune uveitis (EAU). Cytokine 74, 76–80. https://doi.org/10.1016/j.cytog.2014.12.017 (2015).
22. Abu El-Asrar, A. M. et al. Expression of interleukin (IL)-10 family cytokines in aqueous humour of patients with specific endogenous uveitic entities: elevated levels of IL-19 in human leucocyte antigen-B27-associated uveitis. Acta Ophthalmol. 97, e780–e784. https://doi.org/10.1111/aos.14039 (2019).
23. Li, Z. et al. Gene expression profiling in autoimmune noninfectious uveitis disease. J. Immunol. 181, 5147–5157. https://doi.org/10.4049/jimmunol.181.7.5147 (2008).
24. Sawant, D. V. et al. Adaptive plasticity of IL-10(+) and IL-35(+) Treg cells cooperatively promotes tumor T cell exhaustion. Nat. Immunol. 20, 724–735. https://doi.org/10.1038/s41590-019-0346-9 (2019).
25. Kourko, O., Seaver, K., Odoardi, N., Basta, S. & Gee, K. IL-27, IL-30, and IL-35: A cytokine triumvirate in cancer. Front. Immunol. 9, 1069. https://doi.org/10.3389/fimmu.2019.00969 (2019).
26. Xue, W., Yan, D. & Kan, Q. Interleukin-35 as an emerging tumor in patient microenvironment. J. Cancer 10, 2074–2082. https://doi.org/10.7150/jca.29170 (2019).
27. Takeda, A. et al. Distinct profiles of soluble cytokine receptors between B-cell vitreoretinal lymphoma and uveitis. Invest. Ophthalmol. Vis. Sci. 56, 7516–7523. https://doi.org/10.1167/iovs.15-17465 (2015).
28. Nayak, L. et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 129, 3071–3073. https://doi.org/10.1182/blood.2017-01-764209 (2017).
29. Francisco, L. M. et al. PD-1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015–3029. https://doi.org/10.1084/jem.20090847 (2009).
30. Liu, Y. et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol. Immunother. 58, 687–697. https://doi.org/10.1007/s00262-008-0591-5 (2009).
31. Hao, S. et al. Breast cancer cell-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells. Carcinogenesis 39, 1488–1496. https://doi.org/10.1093/carcin/bgy136 (2018).
32. Zhao, Z. et al. Increased interleukin 35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer. Cytokine 89, 76–81. https://doi.org/10.1016/j.cyto.2016.09.012 (2017).
33. Zeng, J. C. et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int. J. Clin. Exp. Pathol. 6, 1806–1816 (2013).
34. Fu, Y. et al. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br. J. Cancer 114, 767–776. https://doi.org/10.1038/bjc.2016.47 (2016).
35. Larousserie, F. et al. Evidence for IL-35 expression in diffuse large B-cell lymphoma and impact on the patient’s prognosis. Front. Oncol. 9, 563. https://doi.org/10.3389/fonc.2019.00563 (2019).
36. Yoshida, H. & Hunter, C. A. The immunobiology of interleukin-27. Annu. Rev. Immunol. 33, 417–443. https://doi.org/10.1146/annurev-immunol-032414-112134 (2015).
37. Ennishi, D. et al. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann. Oncol. 20, 526–533. https://doi.org/10.1093/annonc/mdm577 (2009).
38. Morito, T. et al. Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma. Cancer Sci. 100, 1255–1260. https://doi.org/10.1111/j.1349-7006.2009.01167.x (2009).
39. Goto, N. et al. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen. Ann. Hematol. 91, 705–714. https://doi.org/10.1007/s00275-011-1363-4 (2012).
40. Umino, K. et al. Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Lymphoma 60, 734–741. https://doi.org/10.1080/10428194.2018.1504939 (2019).
41. Yang, Z. Z. et al. Soluble IL-2alpha retains IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 118, 2809–2820. https://doi.org/10.1182/blood-2011-03-340885 (2011).
42. Yoshida, N. et al. Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS ONE 8, e78730. https://doi.org/10.1371/journal.pone.0078730 (2013).
43. Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39–51. https://doi.org/10.1016/j.cell.2010.03.014 (2010).
44. Lu, T. et al. Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin’s lymphoma. Oncotarget 7, 56574–56583. https://doi.org/10.18632/oncotarget.10966 (2016).
45. Di Lallo, G. et al. Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival. Oncotarget 4, e1005460. https://doi.org/10.18632/oncotarget.1095460 (2015).
46. Gelebart, P., Zak, Z., Dien-Bard, J., Anand, M. & Lai, R. Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. Transl. Oncol. 4, 9–19. https://doi.org/10.1593/tlo.10172 (2011).
47. Ito, T. et al. Risk factors for failure of vitrectomy cell block technique in cytological diagnosis of vitreoretinal lymphoma. Graefes. Arch. Clin. Exp. Ophthalmol. 257, 1029–1036. https://doi.org/10.1016/j.gata.2019.04.026 (2019).

Acknowledgements
This work was supported by a grant from Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 18K09471 from the Ministry of Education, Science, Sports and Culture, Japan, and grants from Novartis Pharma Research Grants (AT; Tokyo, Japan) and Alcon Pharma Research Grants (AT; Tokyo, Japan). The funding sources had no role in the design and conduct of the study.

Author contributions
Concept and design of the work: A.T.; Acquisition or interpretation of data: A.T., S.N., K.I., Y.M., T.H., M.A., N.Y., Y.O., H.Y.; Analysis of data: A.T.; Statistical analysis: E.H.; Critical revision of the article: K.K., KH.S.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to A.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020